Singapore Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Singapore Breast Cancer Therapeutics Market Analysis

$ 3999

The Singapore breast cancer therapeutics market is growing from $22 Mn in 2022 to $xx Mn in 2030 with a CAGR of xx% for the forecasted year 2022-2030 due to the changing lifestyle choices leading to obesity and rising incidence of breast cancer in Singapore. The market is segmented by therapy, by cancer type, and by distribution channel. Beacons Pharmaceuticals, Bristol-Myers Squibb Co., and Eli Lilly and Co. are the leading companies in the Singapore breast cancer therapeutics market.

ID: IN10SGPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Parul Choudhary

Buy Now

Singapore Breast Cancer Therapeutics Market Executive Analysis

The Singapore breast cancer therapeutics market size is at around $22 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. The Ministry of Health (MOH) expects to spend $19.29 Bn overall in Financial Year 2022 (FY2022), which is $0.86 Bn or 4.7% more than the total spending for FY2021 as revised. The Ministry of Health Headquarters Programme has been given a budget of $7.52 Bn, which covers funding for new and ongoing healthcare personnel initiatives, training for the healthcare industry, research, premium support for MediShield Life, as well as other grants and financial aid. The Program also funds the Health Sciences Authority to help regulatory and compliance organizations in the health and non-health sectors protect the public's health.

Breast cancer, with an age-standardized incidence rate of 54.9 per 100,000 per year, is the most prevalent malignancy among Singaporean women, accounting for 29.7% of all female malignancies. It has been the most common malignancy among Singaporean women for the past 30 years. Previously, the peak age range was reported to be women in their late 50s, but more recent research has shown that this is no longer the case. Breast cancer affects about 270 people per year in Singapore and results in approximately 1,100 new cases being diagnosed each year. Detecting breast cancer early is the goal of Singapore's national breast cancer screening programme. Mammography screening should be done every two years for women aged 50 to 69, according to the programme.

Breast-conserving surgery, lumpectomies, and mastectomy are among the surgical treatments available in Singapore as the most prevalent method of treatment for breast cancer. After surgery, radiation therapy is used to eliminate any cancer cells that could still be present. It can also be used to reduce a tumour before surgery. Cancer cells are eliminated from the body through chemotherapy, targeted therapy, and hormone therapy.

singapore breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

Increasing rates of female alcohol consumption, hormone replacement therapy (HRT) use, and oral contraceptive pill use all lead to greater levels of oestrogen in the body, which will result in a growth in the Singapore breast cancer therapeutics market over the course of the projection period. The chance of developing the disease also rises with increasing exposure to certain carcinogens and endocrine disruptors, such as working night shifts at work, which is majorly driving the growth of the Singapore breast cancer therapeutics market.

Market Restraints

Lack of access to newer medications and the high cost of some targeted therapies like Trastuzumab and Lapatinib as well as hormonal therapy are some of the main barriers to market expansion in Singapore. Inadequate healthcare infrastructure and reimbursement rules may hinder the growth of the breast cancer treatment market in Singapore.

Competitive Landscape

Key Players

Raffles Medical Group (SGP)
Sphaera Pharma (SGP)
MSD Singapore (SGP)
Beacons Pharmaceuticals (SGP)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

Through the MediShield Life and MediSave programmes, the government of Singapore pays for breast cancer treatment. Hospitalization expenses and some outpatient procedures, including breast cancer treatment, are covered by the compulsory health insurance programme MediShield Life. A %age of one's income can be set aside by using MediSave, a national savings programme, for medical expenses, including costs associated with breast cancer. Through the MediFund programme, the government also offers financial support to people with lower incomes. Government hospitals only reimburse for pre-approved treatment plans that include surgery, chemotherapy, and radiation therapy for breast cancer patients. Patients who opt to receive care at private hospitals must pay out of pocket or with private insurance, but they may also be eligible for MediShield Life and MediSave benefits.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.